• Slowed papillary reaction to direct light (possible rebound dilation)
• Smooth pursuit; no nystagmus, no lack of convergence.
• Fast internal clock (possibly 15 seconds or less for 30 seconds)
• Fast speech (repetitive speech at excessive doses)
• Hyperactivity (but not in all cases . . . hint, hint)
• Hyperflexia (exaggerated motions and movements, but not in all cases)
• Grimacing and other dystonic reactions (excessive, abusive doses)
• Perspiration and flushed facial appearance Users feel a substantial boost to their over-
all sense of energy. Tey may also experience a reflective sense of great cognitive abilities and intellectual competitiveness. Others
may find it capable of stimulating athletic performance. Rita Panizzon did. She cited the drug’s efficacy as aiding her prowess on the tennis court. In its base form, the drug exerts its effects for 4-6 hours. In extended release formats, the drug can be pharmacologically active for 12 or more hours. Tis month’s drug is regulated and
controlled under the terms and conditions of Federal Schedule II. And like other drugs assigned to Schedule II, this month’s drug is the subject of extensive diversion and abuse. Tis drug is still frontline therapy in the treatment of atention deficit-hyperactivity disorder, a condition widely known by its initials of ADHD. In that role, this month’s drug is an alternative therapeutic choice to the use of amphetamine. And although this drug is not approved for use in children
under the age of 6, it is immensely popular in older children and adolescent setings. Te drug is also a preference of adults who have been diagnosed with later stage forms of ADHD. Newer drugs may be edging this month’s drug from the frontlines of ADHD pharmacotherapy. ❚
Rita Panizzon’s experience led to early nomen- clature as “Ritaline.” A subsequent iteration of the drug was coined, “Ritalin.” Beyond Ritalin, this month’s drug is showcased in preparations, such as Concerta and Methylin. Daytrana is a transdermal patch and delivery system for this drug, although it is struggling to get traction as an alternative to the traditional oral preparations.
This month’s drug: methylphenidate; brand names (Ritalin, Concerta, Methylin, Biphenta and Daytrana)
Its So E ’ Colle
ct S mple Combine:
a • EZSC E NEW: EZ-SCREEN® Cup 800-832-3244 ·
www.medtox.com www.datia.org datia focus 41
- REN • eC i
® Cup
han E c • MD
® ( letronic Chino-u dy E TOX Laboraory Cnrmtions
t
a -fCsto ) ofi a
For a Comprehensive Employment Test System
Z. . R d R ea esults.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46